摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Quinazolineacetic acid | 933709-01-4

中文名称
——
中文别名
——
英文名称
Quinazolineacetic acid
英文别名
2-quinazolin-2-ylacetic acid
Quinazolineacetic acid化学式
CAS
933709-01-4
化学式
C10H8N2O2
mdl
——
分子量
188.18
InChiKey
JFQOVQOJGWHXJP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    63.1
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents
    申请人:Wunberg Tobias
    公开号:US20070185121A1
    公开(公告)日:2007-08-09
    The invention relates to heterocyclyl-substituted dihydroquinazolines of formula (I), to processes for their preparation, to medicaments containing them, and to methods for the treatment and/or prophylaxis of diseases, in particular, for use as anti-viral agents, in particular, against cytomegaloviruses.
    这项发明涉及公式(I)的杂环基取代的二氢喹唑啉,以及它们的制备方法、含有它们的药物,以及用于治疗和/或预防疾病的方法,特别是作为抗病毒剂,特别是针对巨细胞病毒。
  • [EN] AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS<br/>[FR] AMINOPYRIMIDINES COMME INHIBITEURS DE SORBITOL DESHYDROGENASE
    申请人:PFIZER PROD INC
    公开号:WO2000059510A1
    公开(公告)日:2000-10-12
    This invention is directed to sorbitol dehydrogenase inhibitory compounds of formula (I), wherein R?1, R2 and R3¿ are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefor at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula (I) of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula (I) of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula (I) and to processes for preparing those intermediates.
    本发明涉及式(I)的山梨醇脱氢酶抑制剂,其中R1、R2和R3在说明书中定义。本发明还涉及含有这些化合物的药物组合物,以及通过将这些化合物用于患有糖尿病并因此有患上这些并发症风险的哺乳动物进行治疗或预防糖尿病并发症,特别是糖尿病神经病变、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病的方法。本发明还涉及一种包含本发明式(I)化合物和醛还原酶抑制剂的药物组合物以及用于治疗或预防糖尿病并发症的方法。本发明还涉及一种包含本发明式(I)化合物和NHE-1抑制剂的药物组合物以及用于治疗心肌病和其他心脏相关问题的方法。本发明还涉及用于合成式(I)化合物的某些中间体以及制备这些中间体的方法。
  • [EN] N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA<br/>[FR] DERIVES DE LA N-[(A CYCLE DI OU TRIAZA DIINSATURE SUBSTITUE) CARBONYLE] GUANIDINE UTILISES POUR LE TRAITEMENT DE L'ISCHEMIE
    申请人:PFIZER PRODUCTS INC.
    公开号:WO1999043663A1
    公开(公告)日:1999-09-02
    (EN) NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.(FR) L'invention porte sur des inhibiteurs du NHE-1, sur leurs procédés d'utilisation, et sur des préparations pharmaceutiques les contenant. Lesdits inhibiteurs servent à réduire les dommages tissulaires résultant de l'ischémie des tissus.
    NHE-1抑制剂,使用这种NHE-1抑制剂的方法以及含有这种NHE-1抑制剂的药物组合物。这些NHE-1抑制剂有助于减少组织缺血引起的组织损伤。
  • [EN] COMPOUNDS FOR THE TREATMENT OF ISCHEMIA<br/>[FR] COMPOSES DESTINES AU TRAITEMENT D'ISCHEMIE
    申请人:PFIZER PROD INC
    公开号:WO2001023399A1
    公开(公告)日:2001-04-05
    A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.
    A3激动剂,使用这种A3激动剂的方法和含有这种A3激动剂的药物组合物。这些A3激动剂对于减少组织缺血或低氧引起的组织损伤非常有用。
  • COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR
    申请人:Pfizer Products Inc.
    公开号:EP1032424A1
    公开(公告)日:2000-09-06
查看更多